Introduction {#s1}
============

Rationale
---------

With 34.2 and 13.6 lung cancer cases per 100,000 per year for men and women around the world, respectively, lung cancer has the highest incidence rate for men and the fourth highest incidence rate for women ([@B1]). Regarding mortality, lung cancer has the highest rate in men and the second highest rate in women worldwide ([@B1]). Five-year survival rates vary considerably across countries with estimates between 10 and 20 % ([@B2]). These differences were even observed when comparing countries of similar structures in health care and access to care, such as the Scandinavian countries Sweden, Norway, and Denmark ([@B3]). Variations in the distribution of prognostic factors, such as stage, are likely to at least partly explain these differences ([@B3]). Numerous other prognostic factors have been investigated which include tumor-related factors like lung cancer subtype but also patient-related factors, such as age, gender, and comorbidities as well as smoking status and cancer treatment ([@B4]). For example, a later stage at diagnosis, male gender and current smoking at diagnosis have been shown to predict poor prognosis in lung cancer patients ([@B5]--[@B7]).

Another well-established prognostic factor for various cancer sites is socioeconomic status (SES) ([@B8]). Socioeconomic differences in cancer survival have been investigated and summarized by systematic reviews for different cancer types, such as breast ([@B9], [@B10]), colorectal ([@B11]), and prostate cancer ([@B12]). A recent meta-analysis reported lower breast cancer survival for women with lower SES even after adjustment for tumor characteristics, treatment, comorbidity or lifestyle-factors ([@B10]). Manser and Bauerfeind ([@B11]) reported in their systematic review significantly lower 1- and 5-year colorectal cancer survival rates for the lowest socioeconomic group compared to the highest socioeconomic group. Generally for all cancer types, neither stage at diagnosis nor treatment factors could entirely explain the association between SES and cancer survival ([@B13]).

For lung cancer, socioeconomic differences in incidence, mortality and treatment patterns have been summarized in systematic reviews, meta-, and pooled-analyses. A meta-analysis reported an increased risk in lung cancer incidence for lower socioeconomic groups with similar effect estimates in studies adjusting and not adjusting for smoking status ([@B14]). These results were confirmed by a recent international pooled analysis of case-control studies including detailed information on occupations and smoking behavior of around 17,000 cases and 20,000 controls ([@B15]). An analysis including 16 European populations reported higher lung cancer mortality rates in groups with lowest educational attainment ([@B16]). Another systematic review focused on lung cancer and showed higher lung cancer incidence and mortality in socioeconomically deprived areas ([@B17]). Tumor stage was not found to be associated with deprivation. However, stage might still confound associations between deprivation and lung cancer survival ([@B18]). Regarding treatment of lung cancer ([@B19]), the probability of receiving any type of treatment, surgery, and chemotherapy was lower in more deprived groups compared to the least deprived groups ([@B19]). To date, a systematic summary of findings regarding socioeconomic differences and lung cancer survival outcomes has not yet been provided.

SES can be measured for each patient individually (for example via questionnaire) or by using an ecological approach, meaning that a particular SES level is assigned to the residential area of each study participant ([@B20]). The latter can be called area-based studies which are often conducted if no individual SES data are available or if the effect of the area-based SES on health-related outcomes of a study participant is investigated ([@B20]). In such area-based studies, the aggregation level might be important. For patients with a diagnosis of breast cancer resident in England, it has been shown that the difference in crude survival between the most and the least deprived groups was 25 % smaller when using larger geographic units compared to smaller units ([@B21]). This dilution effect is caused by an increase in social heterogeneity the larger the area-level is ([@B21]). Another example from Australia reported stronger associations between socioeconomic disadvantage and the risk of cancer death and a more consistent socioeconomic gradient for the smaller geographical unit ([@B22]). However, this effect has not been investigated for lung cancer and has often been neglected in systematic reviews and meta-analyses. Furthermore, detailed meta-analyses regarding prognostic factors and their potential confounding in the association between socioeconomic measures and lung cancer survival have not yet been provided.

Objectives
----------

In our systematic review and meta-analysis, we provide a comprehensive summary on the current literature on socioeconomic differences in lung cancer survival with a focus on the impact of aggregation and adjustment level. The results of our review may inform health care planners about disparities in the prognosis of lung cancer patients and might help to more precisely identify socioeconomic deprived groups to counteract these differences.

Research question
-----------------

We investigated three research questions:

1.  What is the current state of research on socioeconomic differences in lung cancer survival with regard to studies measuring individual or aggregated socioeconomic status?

2.  To what extend does a potential gradient in lung cancer survival by socioeconomic status vary by level of exposure definition (e.g., individual level, community level)?

3.  Which prognostic factors have an impact on differences in socioeconomic status, particularly regarding the association with lung cancer survival?

Methods {#s2}
=======

Systematic review protocol
--------------------------

The systematic review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines ([@B23]) and the extended version for equity-focused systematic reviews PRISMA-E 2012 ([@B24]). This review is registered in the international prospective register for systematic reviews PROSPERO ([www.crd.york.ac.uk/](http://www.crd.york.ac.uk/)PROSPERO, registration number: CRD42017072607).

Literature search
-----------------

The main information sources for the literature search were four databases: Medline/PubMed (1966 to December 6, 2017), Web of Science (Science Citation Index Expanded, Social Science Citation Index, 1945 to December 7, 2017), The Cochrane Library (1992 to December 6, 2017), and GESIS Sowiport (1910 to December 8, 2017). The online portal Sowiport is organized by the GESIS Leibniz Institute for the Social Sciences ([@B25]) and included several social science related databases until its termination in December 2017. For our search strategy, a combination of key words regarding lung cancer survival and SES was applied. Key words related to SES were for example: socioeconomic, deprivation, disparit^\*^, segregation, education, income, occupation, \[social AND (status OR class OR position OR inequality^\*^)\]. The detailed search strategies for all databases including the respective thesaurus terms are displayed in Table [S1](#SM1){ref-type="supplementary-material"}. In addition, reference lists of included papers have been searched.

Inclusion and exclusion criteria---population
---------------------------------------------

To be eligible, studies had to investigate a population of patients with a primary diagnosis of lung cancer. If other cancer sites were additionally investigated, studies were only included if results for lung cancer patients were reported separately.

Inclusion and exclusion criteria---exposure(s)
----------------------------------------------

We focused our search on the main socioeconomic factors education, income and occupation as explanatory variable, measured either on an individual or area-based level. As many area-based studies used combined SES measurements, also called indices, we additionally included all combined measures or indices. Categorical and continuous measurements of socioeconomic measures were included.

Inclusion and exclusion criteria---outcome
------------------------------------------

The primary outcome of interest is survival after lung cancer diagnosis reported stratified by socioeconomic group. We focused on effect estimates from survival regression models (Cox or Poisson), 1-, 3-, or 5-year survival rates and median survival time after diagnosis. Other measures of survival were additionally included. The description of our results in the text focused on the regression models and 5-year survival rates.

Inclusion and exclusion criteria---types of studies
---------------------------------------------------

Observational studies published in a peer-reviewed journal in English or German language were eligible for inclusion in our review. Non-original articles, such as guidelines, comments, book-chapters, editorials, reviews, and methods-papers were excluded. There was no further restriction regarding the period of publication or the study design.

Inclusion and exclusion criteria---meta-analysis
------------------------------------------------

To be eligible for inclusion in our meta-analysis, included studies had to fulfill further criteria. First, a study had to report hazard ratios including respective 95 % confidence intervals. Second, the studies should report on the same socioeconomic measure in a comparable manner to be able to combine the results in a meta-analysis. Third, socioeconomic measures had to be reported as categorical variables to identify low SES and high SES groups. Lastly, studies had to have a quality score of at least 6 out of 8 stars (for definition of the score see quality assessment below). This criterion was defined after writing the review protocol but before study results were summarized and interpreted. A cut-off of 6 was chosen by trading off the aim to include as many studies as possible against the aim to guarantee a high quality of the included studies. However, we additionally conducted sensitivity analyses including all studies irrespective of the quality score. In case of overlapping populations, we decided to hierarchically include the study with the most comprehensive inclusion of all stage groups, the longest period of diagnosis, and the longest follow-up period.

Study selection and data extraction/screening
---------------------------------------------

Titles, abstracts, and full texts retrieved were screened by one reviewer (IF). If no full text was available, studies were excluded if published before 1980, otherwise retrieved from The German National Library of Medicine (ZB MED) ([@B26]). EndNote software X7 was used to remove duplicates, retrieve full text articles, and manage citations. Data extraction of relevant information from included studies was performed by at least two reviewers for each study (IF, LW, and GB). Disagreements were resolved through discussion with a fourth member (LJ) of the review team. If relevant information was not reported in a study, the corresponding author was contacted via email. Sixteen authors were contacted and 10 answered to our request. Data items extracted from articles included the following: First author, publication year, country, study type, study setting, sample characteristics (n, age, gender), measure of SES (education, income, occupation, index), level of measurement (individual/area-based), outcome measure, prognostic factors, risk of bias evaluation and main results. If a study used two different SES measurements separately, results for both measures were extracted. Model results were reported for the full model including all adjustments.

Quality assessment
------------------

To assess the methodologic and reporting quality of included studies, a modified version of the Newcastle-Ottawa-Scale (NOS) was used ([@B27]). The NOS consists of seven items to judge the quality of a study regarding the selection and comparability of study groups and ascertainment of the outcome (cohort studies) or exposure (case-control studies). One star was awarded for each item, except the comparability item which was modified so studies controlling for age in their analysis were awarded with one star and one additional star if any other factor was controlled for. In total, a study could be awarded with a maximum of 8 stars. We did not restrict the coding manual to a specific follow-up length, as the assessment of an adequate follow-up period refers to the study aim of the respective article. For example, if a study reported 3 months survival rates, the follow-up period had to be at least 3 months. The coding manual of our modified NOS can be found in the Supplementary Material.

Statistical analysis and sensitivity analysis
---------------------------------------------

We computed random effects models and assessed heterogeneity across studies by using *I*^2^ and Q statistics ([@B28]). The inverse variance method was used to assign the weight of each study in the analysis. For each study, we compared hazard ratios of the lowest SES group with the highest SES group as a reference. This was necessary as the categorizations of socioeconomic measures were very heterogeneous between the studies. Subgroup analyses were performed if possible by adjustment for smoking status, stage, and treatment. To assess the possible risk of bias and heterogeneity across studies included in our meta-analyses, we generated funnel plots and performed Begg\'s and Egger\'s test of plot asymmetry. All analyses were performed in the R statistical software (version 3.3.1) by using the metafor library (version 2.0-0).

Results {#s3}
=======

Study selection and characteristics
-----------------------------------

Based on our search strategy, the initial search resulted in 5,532 publications potentially relevant for the systematic review (Figure [1](#F1){ref-type="fig"}). After title and abstract screening, 196 articles were selected for full-text screening. Assessment of the full-texts led to the exclusion of 117 articles, mainly due to not investigating survival after lung cancer or not using a measure of education, income, occupation or an index. Fifteen publications were identified by reviewing of reference lists of included articles ([@B29]--[@B43]). In total, 94 articles ([@B5], [@B6], [@B22], [@B29]--[@B119]) were included in the qualitative synthesis and 17 ([@B44]--[@B48], [@B54]--[@B56], [@B60]--[@B62], [@B88], [@B90], [@B98], [@B112], [@B114], [@B115]) of these were eligible to be included in the meta-analyses.

![PRISMA flow diagram of study selection process for a systematic review and meta-analysis on socioeconomic differences and lung cancer survival.](fonc-08-00536-g0001){#F1}

Characteristics of included studies are shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. There were 23 studies ([@B30], [@B32], [@B39], [@B42], [@B44]--[@B62]) reporting on socioeconomic measures on individual level (Table [1](#T1){ref-type="table"}), 70 studies ([@B5], [@B6], [@B22], [@B29], [@B31], [@B33], [@B35]--[@B38], [@B40], [@B41], [@B43], [@B63]--[@B119]) reporting on area-based level (Table [2](#T2){ref-type="table"}) and one study reporting on both levels ([@B34]) (Table [2](#T2){ref-type="table"}). One study included both individual and aggregated measures and performed a multilevel analysis ([@B34]) (Table [2](#T2){ref-type="table"}). Most studies have been published within the last 10 years. Studies on individual SES measures used mostly data from Scandinavia, the United States (US) and Italy, while the majority of studies including area-based SES measures used data from the US, Great Britain and Australia/New Zealand. Data sources for cancer survival were usually national cancer registries but also cohort studies and clinical trials ([@B50], [@B53]). Most studies reported on all types of lung cancer, but 20 studies restricted analyses to non-small-cell lung cancer (NSCLC) patients ([@B5], [@B34], [@B44], [@B45], [@B50], [@B56], [@B63], [@B66], [@B68], [@B72], [@B76], [@B80], [@B88]--[@B90], [@B93], [@B96], [@B97], [@B101], [@B112], [@B115]) and three studies were restricted to small-cell lung cancer (SCLC) patients ([@B6], [@B92], [@B114]).

###### 

Characteristics of included studies with individual measurements of socioeconomic status.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Paper, Data source[^1^](#TN1){ref-type="table-fn"}**   **Country**   **Years of diagnosis, Follow-up length, Age (range)**                **Sample size[^2^](#TN2){ref-type="table-fn"}**   **SES indicator(s)**[^**3**^](#TN3){ref-type="table-fn"}   **Outcome**   **Adjustment**[^**4**^](#TN4){ref-type="table-fn"}   **QS**                                                                                                                                                       
  -------------------------------------------------------- ------------- -------------------------------------------------------------------- ------------------------------------------------- ---------------------------------------------------------- ------------- ---------------------------------------------------- -------- --- --- -------- --- ----------------------------------- --- --- --- --- ------------------------------------- ------------------------------------ ---
  **EUROPE, NORTH**                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Dalton et al. ([@B49]), PBC (REG)                        Denmark       1994--2003, FU: 2006, 30--79 yrs                                     21,492                                            3                                                          3             3.6[^5^](#TN5){ref-type="table-fn"}                                   1,5,KM       X                                       X   X                                                                                  8

  Dalton et al. ([@B48]), PBC (REG)                        Denmark       2004--2010, FU: 2011, 51--81 yrs                                     13,045                                            3                                                          3                                                                           X                X                                           X   X   X                                         X[^a^](#TN13){ref-type="table-fn"}   8

  Pokhrel et al. ([@B39]), PBC (REG)                       Finland       1971--2005, FU: 2005, ≥25 yrs                                        66,014                                            3                                                                                                                                              5        X   X                                   X   X   X                                                                                  8

  Kravdal ([@B55]), PBC (REG)                              Norway        1955--1986, FU: 1960--1991, 50--79 yrs                               NA[^6^](#TN6){ref-type="table-fn"}                4                                                                        14[^7^](#TN7){ref-type="table-fn"}                            X                                                            X   X   X                                         X[^b^](#TN14){ref-type="table-fn"}   7

  Skyrud et al. ([@B58]), PBC (REG)                        Norway        2002--2011, FU: 2013, ≤ 30 yrs                                       24,565                                            3                                                          3                                                                                                X[^8^](#TN8){ref-type="table-fn"}       X   X   X                                         X[^c^](#TN15){ref-type="table-fn"}   8

  Berglund et al. ([@B45]), PBC (REG)                      Sweden        1996--2004, FU: 2006, 30--94 yrs                                     3,370 (NSCLC)                                     3                                                          2             2                                                             X       1,3                                              X   X   X   X   X                                     X[^d^](#TN16){ref-type="table-fn"}   8

  Hussain et al. ([@B54]), PBC (REG)                       Sweden        1990--2004, FU: 2004, 30--64 yrs                                     17,936                                            4                                                                                                                                      X                                                        X   X   X                                             X[^e^](#TN17){ref-type="table-fn"}   7

  Vågerö et al. ([@B59]), PBC (REG)                        Sweden        1961--1979, FU: 1979, 20--64 yrs                                     7,817                                                                                                                      3                                                                     5,KM         X                                           X                                                                                  7

  **EUROPE, OTHER**                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Grivaux et al. ([@B52]), PCo                             France        2000, FU: 2005--2006, all ages                                       5,447                                                                                                                      7                                                                     5        X                                                                                                                                  4

  Di Maio et al. ([@B50]), CT                              Italy         1996--2005 (conduction of trials),\                                  1,680 (NSCLC)                                     2                                                                                                                                      X   X   KM       X                                               X   X                                         X[^f^](#TN18){ref-type="table-fn"}   4
                                                                         FU: median 26.3 mths, 29--86 yrs                                                                                                                                                                                                                                                                                                                                                                                  

  Pagano et al. ([@B56]), PBC (REG)                        Italy         2000--2003, FU: 2006, all ages                                       2,259 (NSCLC)                                     3                                                                                                                                      X                X                                           X   X   X                                         X[^g^](#TN19){ref-type="table-fn"}   8

  Pastorino et al. ([@B57]), PBC (REG)                     Italy         1976--1979, FU: ≥ 9 yrs, 34--85 yrs                                  222                                                                                                                        3                                                                     5        X                                                                                                                                  6

  Smailyte et al. ([@B42]), PBC (REG)                      Lithuania     2001--2009, FU: 2009, 30--74 yrs                                     8,812                                             3                                                                                                                                              5            X                                       X   X                                                                                  8

  Aarts et al. ([@B44]), PBC (REG)                         NL            1991--2008, FU: 2009, 15--75 yrs                                     274 (NSCLC)                                       4                                                                                                                                      X       1,3,KM   X                                           X   X   X   X                                     X[^h^](#TN20){ref-type="table-fn"}   7

  **USA**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Chirikos et al. ([@B30]), PBC (REG)                      USA           1977--1981, FU: NA, Age: NA                                          NA[^9^](#TN9){ref-type="table-fn"}                                                                           2             2                                                                     1,3,KM                                           X           X                                                                              8

  Clement-Duchene et al. ([@B47]), PCo                     USA           2003--2005, FU: 2012, all ages                                       3,410                                             3                                                          4                                                                           X                                                            X   X   X   X[^10^](#TN10){ref-type="table-fn"}   X[^i^](#TN21){ref-type="table-fn"}   8

  Herndon et al. ([@B53]), CT                              USA           1988--2001[^11^](#TN11){ref-type="table-fn"}, FU:2005, all ages      1,577                                             5                                                                                                                                      X   X   KM       X                                                                                                                                  1

  **ASIA**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Yeole et al. ([@B61]), PBC (REG)                         India         1987--1991, FU: until 1996, all ages                                 1,995                                             4                                                                                                                                      X       5            X                                       X       X                                         X[^j^](#TN22){ref-type="table-fn"}   8

  Yeole et al. ([@B60]), PBC (REG)                         India         1992--1994, FU: until 1999, all ages                                 1,230                                             4                                                                                                                                      X       5        X                                           X       X                                         X[^k^](#TN23){ref-type="table-fn"}   8

  Fujino ([@B51]), CoS                                     Japan         1988--1990[^12^](#TN12){ref-type="table-fn"}, FU: 2003, 40--79 yrs   1,098                                             3                                                                                                                                      X                                                            X   X                                             X[^l^](#TN24){ref-type="table-fn"}   5

  Fujino ([@B32]), CoS                                     Japan         1988--1990[^12^](#TN12){ref-type="table-fn"}, FU: 2003, 40--79 yrs   NA                                                                                                                         6,3,4[^5^](#TN5){ref-type="table-fn"}                         X                                                            X   X                                             X[^l^](#TN24){ref-type="table-fn"}   5

  Yim et al. ([@B62]), RCo                                 Korea         2000, FU: ≤ 48 mths, all ages                                        261                                                                                                          3                                                                           X       3,KM     X                                       X   X   X   X                                         X[^m^](#TN25){ref-type="table-fn"}   7

  Chang et al. ([@B46]), PGB (INS)                         Taiwan        2002, FU: 5 years, all ages                                          4,698                                                                                                        6                                                                           X       5,KM     X                                           X   X   X                                         X[^n^](#TN26){ref-type="table-fn"}   8
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*CSS, Cause-specific survival; CoS, Cohort study; CT, Data from clinical trials; FU, Follow-up length; HR, Hazard ratio; mths, months; INS, Insurance; KM, Study provided Kaplan-Meier-Curve(s) or other survival curves stratified by SES; NA, Not available; NL, The Netherlands; NSCLC, Non-small cell lung cancer; OS, Overall survival; PBC, Population-based cohort; PCo, Prospective cohort; QS, Quality score; RCo, Retrospective cohort; REG, Registry; RS, Relative survival; SEER, Surveillance, Epidemiology, and End Results Program; SES, Socioeconomic status; Yrs, years of age*;

*Data sources for survival data*;

*Only lung cancer patients*;

*Numbers indicate number of groups, excluding unknown/missing, more detail in Table [S2](#SM2){ref-type="supplementary-material"}*;

*Adjustment by stratification and standardization was also considered; if both model and survival rates were calculated, only model adjustments are reported*;

*Study assessed two (three) indicators for occupation*;

*Sample size: 114,000 (all cancers)*;

*Combination of education and occupation*;

*Study reported relative excess risk*;

*Sample size: 1,180 (all cancers, only men)*;

*Study included only non-smokers*;

*Enrollment dates*;

*Study start*;

*Comorbidities, first-line treatment, performance status, period*;

*Histologic type/grade, period/year, sub-site*;

*Health services region, radiotherapy, surgery*;

*Histopathology, performance status, treatment*;

*Period*;

*Birth cohort, histology, performance status*;

*Comorbidity, marital status, pattern of care*;

*Alcohol, comorbidities, period, physical activity*;

*Race, comorbidity, insurance, health care setting, histology, surgery, chemotherapy, radiotherapy*;

*Marital status, treatment*;

*Marital status, religion, treatment*;

*Area of study*;

*Family history, out-patient-visits per month, performance status*;

*Comorbidities, hospital characteristics, treatment modality*.

###### 

Characteristics of included studies with aggregated measurements of socioeconomic status.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Paper, Data source[^1^](#TN27){ref-type="table-fn"}**   **Country**      **Years of diagnosis,\                                           **Sample size[^2^](#TN28){ref-type="table-fn"}**          **SESindicator(s)**[^**3**^](#TN29){ref-type="table-fn"}   **SES Level[^4^](#TN30){ref-type="table-fn"}**   **Outcome**   **Adjustment**[^**5**^](#TN31){ref-type="table-fn"}   **QS**                                                                                                                                                                    
                                                                             Follow-up length, Age (range)**                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  --------------------------------------------------------- ---------------- ---------------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------ ------------- ----------------------------------------------------- ---------------------- --- --- --------------------------------------- --- ------------------------------------- --- --- --- --- --- ------------------------------------ ---
  **EUROPE**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Chouaid et al. ([@B70]), RCo                              France           2011, FU: 2013, all ages                                         41,115                                                                                                                                                                              4                                                     Com-mune               X       1,2                                     X                                             X   X           X[^a^](#TN41){ref-type="table-fn"}   7

  Jansen et al. ([@B35]), PBC (REG)                         Germany          1997--2006, FU: 2006, ≥15 yrs                                    105,688                                                                                                                                                                             5                                                     District                       5                                           X[^6^](#TN32){ref-type="table-fn"}        X       X                                            8

  Aarts et al. ([@B63]), PBC (REG)                          NL               2001--2012, FU: 2014, all ages                                   5,428 NSCLC stage IV                                                                                                                                                                4                                                     PC                     X   X   1                                       X                                             X   X           X[^b^](#TN42){ref-type="table-fn"}   8

  Louwman et al. ([@B94]), PBC (REG)                        NL               1997--2006, FU: NA, all ages                                     12,945                                                                                                                                                                              3                                                     PC                     X       1                                       X                                             X   X           X[^c^](#TN43){ref-type="table-fn"}   8

  Schrijvers ([@B106]), PBC (REG)                           NL               1980--1989, FU: 1991, all ages                                   4,591                                                                                                                                                                               5                                                     PC                     X       5                                           X                                         X       X       X[^d^](#TN44){ref-type="table-fn"}   8

  Pollock and Vickers ([@B102]), PBC (REG)                  England          1987--1992, FU: 1992, 40--99 yrs                                 22,842                                                                                                                                                                              10                                                    ED                             5, KM                                       X                                         X   X                                                8

  Schrijvers ([@B107]), PBC (REG)                           England          1980--1989, FU: 1992, 30--99 yrs                                 40,279                                                                                                                                                                              5                                                     ED                     X       5                                           X                                         X   X   X       X[^e^](#TN45){ref-type="table-fn"}   8

  Berglund et al. ([@B64]), PBC (REG)                       England          2006--2008, FU: 2009, 0--80+ yrs                                 15,582                                                                                                               5                                                                                                                    LSOA                   X       3, KM                                   X                                             X   X   X       X[^f^](#TN46){ref-type="table-fn"}   8

  Nur et al. ([@B99]), PBC (REG)                            England          2001--2005, FU: 2011, 15--99 yrs                                 145,532                                                                                                                                                                             5                                                     LSOA                           1,5,\                                       X[^6^](#TN32){ref-type="table-fn"}        X   X                                                8
                                                                                                                                                                                                                                                                                                                                                                                                                       10, KM                                                                                                                                     

  Rachet et al. ([@B40]), PBC (REG)                         England          1996--2006, FU: 2007, 15--99 yrs                                 303,422                                                                                                                                                                             5                                                     LSOA                                                                       X[^7^](#TN33){ref-type="table-fn"}        X   X           X[^g^](#TN47){ref-type="table-fn"}   8

  Riaz et al. ([@B104]), PBC                                England          2003--2007, FU: 2008, all ages                                   150,939                                                                                                              5                                                                                                                    LSOA                           1                                       X                                                 X           X[^h^](#TN48){ref-type="table-fn"}   7

  Rich et al. ([@B105]), PBC                                England          2004--2008 (data entry), FU: 2008, all ages                      60,059                                                                                                                                                                              5                                                     LSOA                   X                                                                                             X   X   X       X[^i^](#TN49){ref-type="table-fn"}   8

  Coleman et al. ([@B71]), PBC (REG)                        England/Wales    1971--1990, FU: 1995, all ages                                   144,604                                                                                                                                                                             5                                                     ED                             1,5                                         X                                         X                                                    7

  Rachet et al. ([@B103]), PBC (REG)                        England/ Wales   1986--1999, FU: 2001, 15--99 yrs                                 392,000                                                                                                              5                                                                                                                    LSOA                           5                                                                                         X           X[^g^](#TN47){ref-type="table-fn"}   6

  Sloggett et al. ([@B41]), PBC                             England/Wales    1981--1997, FU: 2000, ≥45 yrs                                    4,271                                                                                                                                                                 6             5                                                     Ward/IND                                                                   X[^6^](#TN32){ref-type="table-fn"}        X   X           X[^j^](#TN50){ref-type="table-fn"}   8

  Coleman et al. ([@B31]), PBC (REG)                        England/Wales    1986--1990, FU: 2001, 15--99 yrs                                 107,317                                                                                                                                                                             5                                                     Electoral ward                                                             X[^7^](#TN33){ref-type="table-fn"}            X                                                7

  Campbell et al. ([@B29]), PBC (REG)                       Scotland         1991--1995, FU: 1995, all ages                                   19,449                                                                                                                                                                              5                                                     OA                             1                                       X                                                                                                  8

  Shack et al. ([@B108]), PBC (REG)                         Scotland         1986--2000, FU: 2004, 15--99 yrs                                 20,851                                                                                                                                                                              5                                                     Postcode sector                5                                           X                                         X   X                                                8

  Iyen--Omofoman et al. ([@B86]), PCo                       UK               2000--2009, FU: 2009, all ages                                   12,135                                                                                                                                                                              5                                                     OA                     X   X   1,5                                     X                                                                                                  6

  O\'Dowd et al. ([@B100]), PCo                             UK               2000--2013, FU: 3 mths, ≥30 yrs                                  20,142                                                                                                                                                                              5                                                     OA                             1,3 mth                                 X                                                                                                  6

  Cheyne et al. ([@B69]), RCo                               UK               2008--2010, FU: NA, 31--97 yrs                                   1,432                                                                                                                                                                 5             5                                                     LSOA                       X   1                                       X                                                                                                  4

  Ellis et al. ([@B75]), PBC (REG)                          UK               2001--2005, FU: 2009, ≥35 yrs                                    145,206                                                                                                                                                                             5                                                     LSOA                           1,5                                         X[^7^](#TN33){ref-type="table-fn"}            X       X                                        8

  Forrest et al. ([@B78]), PBC (REG)                        UK               2006--2009, FU: ≥ 2 yrs, all ages                                22,967                                                                                                               5                                                                                                                    LSOA                           2                                       X                                                                                                  8

  Jack et al. ([@B87]), PBC (REG)                           UK               1998, FU:NA, all ages                                            695                                                                                                                                                                                 5                                                     Ward                           1                                       X                                                                                                  8

  Vercelli et al. ([@B113]), PBC (REG)                      Europe           1990--1994, FU: ≥ 5 yrs, 65--84 yrs                              657,541                                                                                                              X[^8^](#TN34){ref-type="table-fn"}                                                                                   Country                        5                                           X                                             X                                                7

  Evans and Pritchard ([@B77]), PBC                         Europe/USA       Europe: 1983--1985, USA: 1983--1989, FU: 1995,0--84 yrs          10 countries                                                                                                         X[^8^](#TN34){ref-type="table-fn"}                                                                                   Country                        5                                           X                                         X   X                                                8

  **CANADA/USA**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Mackillop et al. ([@B95]), PBC (REG)                      Canada           1982--1991, FU: NA, Age: NA                                      357,530 all cancers                                                                                                  5                                                                                                                    Postal code            X       5,KM                                                                              X   X   X           X[^k^](#TN51){ref-type="table-fn"}   8

  Booth et al. ([@B66]), PBC (REG)                          Canada           2003--2007, FU: ≥ 1 year, Age: NA                                12,276 NSCLC                                                                                                         5                                                                                                                    Com--munity            X       3,5                                     X                                         X   X       X                                            8

  Dabbikeh et al. ([@B73]), PBC (REG)                       Canada           1993--2009, FU: 2013, all ages                                   122,889                                                                                                              5                                                              5                                                     EA/DA                  X       5                                                                                 X   X   X                                                8

  Boyd et al. ([@B67]), PBC (REG/SEER)                      Canada/USA       1987--1992, FU: 1994, ≥20 yrs                                    NA[^9^](#TN35){ref-type="table-fn"}                                                                                  5                                                                                                                    USA: CeT, Canada: EA   X       5,KM                                                                              X   X   X           X[^g^](#TN47){ref-type="table-fn"}   8

  Gorey et al. ([@B33]), PBC (REG/SEER)                     Canada/USA       Canada:1986--1992, FU: 1993, ≥25 yrs\                            Canada: 58,202\                                                                                                      3                                                                                                                    CeT                            1,5[^10^](#TN36){ref-type="table-fn"}                                                     X                                                8
                                                                             USA:1984, FU: 1991, ≥25 yrs                                      USA: 76,055                                                                                                                                                                                                                                                                                                                                                                                                         

  Zhang--Salomons et al. ([@B43]), PBC (REG/SEER)           Canada/USA       Canada:1989--1993, FU: 1998, ≥25 yrs\                            Canada: 8,209, USA: 15,261                                                                                           5                                                                                                                    CeT                    X       5                                                                                 X   X   X                                                8
                                                                             USA: 1988--1992, FU: 1997,\                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                             ≥25 yrs                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Gomez et al. ([@B79]), PBC (REG)                          USA              2000--2010, FU: 2012, all ages                                   3,832 Chinese ethnicity                                                                                                                                                             5                                                     CBG                    X   X                                           X                                             X   X   X       X[^l^](#TN52){ref-type="table-fn"}   8

  Hastert et al. ([@B82]), PBC (SEER)                       USA              2000--2002, FU: 2010, 50--76 yrs                                 52,186                                                    4                                                          5                                                              5                                                     CBG                    X                                                                                             X   X           X[^m^](#TN53){ref-type="table-fn"}   8

  Lara et al. ([@B92]), PBC (REG)                           USA              1998--2012, FU: 2013, all ages                                   22,863 SCLC                                                                                                                                                                         2                                                     CBG                    X                                                                                         X   X   X   X       X[^n^](#TN54){ref-type="table-fn"}   8

  Ou et al. ([@B5]), PBC (REG)                              USA              1989--2003, FU: median 53 mths, all ages                         19,702[^14^](#TN40){ref-type="table-fn"} NSCLC, stage I                                                                                                                             5                                                     CBG                    X                                                                                             X   X   X       X[^N^](#TN75){ref-type="table-fn"}   8

  Ou et al. ([@B101]), PBC (REG)                            USA              1989--2003, FU: median 53 mths, all ages                         19,702[^14^](#TN40){ref-type="table-fn"} NSCLC, stage I                                                                                                                             5                                                     CBG                    X   X   5,KM                                    X                                             X   X           X[^o^](#TN55){ref-type="table-fn"}   8

  Ou et al. ([@B6]), RCo                                    USA              1991--2005, FU: ≥77 mths, all ages                               3,428 ED-SCLC                                                                                                                                                                       5                                                     CBG                    X   X   1,2                                     X                                             X   X       X   X[^p^](#TN56){ref-type="table-fn"}   7

  Caposole et al. ([@B68]), PBC (REG)                       USA              1998--2012, FU:\>12 yrs, all ages                                3,531 NSCLC                                                                                                          4                                                                                                                    CeT                        X                                           X                                                                                                  6

  Erhunmwunsee et al. ([@B76]), PBC (REG)                   USA              1995--2007, FU: ≥2 yrs, 20--105 yrs                              4,820 NSCLC                                               2                                                          2                                                                                                                    CeT                        X   6,KM                                                                              X                                                        5

  Greenwald et al. ([@B34]), PBC (REG)                      USA              1980--1982, FU: 1987, Mean age 67.6 yrs                          78 (NSCLC, stage II)                                                                                                 X                                                                                                                    Multi-\                X                                                                                             X   X                                                8
                                                                                                                                                                                                                                                                                                                                                                                        level (CeT+\                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                        IND)                                                                                                                                                                      

  Greenwald et al. ([@B80]), PBC (SEER)                     USA              1978--1982, FU: ≥10 yrs, ≤ 75 yrs                                5,132 NSCLC                                                                                                          10                                                                                                                   CeT                    X       5                                       X                                             X   X           X[^q^](#TN57){ref-type="table-fn"}   8

  Johnson et al. ([@B88]), PBC (REG)                        USA              2000--2009, FU: 2011, 50--85 yrs                                 32,711 NSCLC                                              4                                                          4                                                                                                                    CeT                    X                                               X                                             X   X   X       X[^r^](#TN58){ref-type="table-fn"}   8

  Johnson et al. ([@B89]), PBC (REG)                        USA              2000--2009, FU: 2012, 30--85 yrs                                 8,322 early stage NSCLC                                   4                                                          4                                                                                                                    CeT                    X                                                                                             X   X           X[^s^](#TN59){ref-type="table-fn"}   8

  Lara et al. ([@B93]), PBC (REG)                           USA              1998--2009, FU: 2011, all ages                                   114,451 NSCLC                                                                                                                                                                       3                                                     CeT                    X   X                                                                                     X   X   X   X       X[^t^](#TN60){ref-type="table-fn"}   8

  Lipworth et al. ([@B38]), PBC (REG)                       USA              1959--1963, FU: 3 yrs, all ages                                  246                                                                                                                  2                                                                                                                    CeT                            1,3                                         X                                             X                                                5

  Niu et al. ([@B98]), PBC (REG)                            USA              1986--1999, FU: 2004, all ages                                   64,206                                                                                                               4                                                                                                                    CeT                    X       5                                                                                 X   X   X   X       X[^u^](#TN61){ref-type="table-fn"}   8

  Shugarman et al. ([@B109]), PBC (SEER)                    USA              1995--1999, FU: NA, ≥65 yrs                                      26,073                                                                                                               3                                                                                                                    CeT                    X                                                                                             X   X   X       X[^v^](#TN62){ref-type="table-fn"}   7

  Tannenbaum et al. ([@B112]), PBC (REG)                    USA              1996--2007, FU: ≥3 yrs, 18--104 yrs                              98,541 NSCLC                                                                                                         4                                                                                                                    CeT                    X   X   1,3,5, KM                               X                                                 X   X   X   X[^w^](#TN63){ref-type="table-fn"}   8

  Yang et al. ([@B117]), PBC (REG)                          USA              1998--2002, FU: 2006, all ages                                   97,046                                                                                                               4                                                                                                                    CeT                    X   X   KM                                      X                                             X   X   X   X   X[^x^](#TN64){ref-type="table-fn"}   8

  Yu et al. ([@B118]), PBC (SEER)                           USA              2000--2002, FU: ≥5 yrs, Age: NA                                  97,046                                                                                                                                                                              5                                                     CeT                                                                                                              X                                                        7

  Khullar et al. ([@B90]), PBC (NCDB)                       USA              2003--2006, FU: NA, Mean 66.0 yrs ± SD 10.33 yrs                 92,929 NSCLC                                              4                                                          4                                                                                                                    Zip code               X       KM                                      X                                             X   X   X       X[^y^](#TN65){ref-type="table-fn"}   8

  McMillan et al. ([@B96]), PBC (NCDB)                      USA              2004--2012, FU: 2013, all ages                                   14,154 NSCLC, stage III                                                                                              2                                                                                                                    Zip code               X                                               X                                             X   X           X[^z^](#TN66){ref-type="table-fn"}   8

  Melvan et al. ([@B97]), PBC (NCDB)                        USA              2003--2011 (resection date),FU: 30 days, ≥60 yrs                 215,645 NSCLC                                             4                                                          4                                                                                                                    Zip code                       30day                                   X                                                                                                  6

  Wen and Christakis ([@B116]), PBC (REG)                   USA              1993, FU: 1999, all ages                                         NA                                                                                                                                                                                  X[^11^](#TN37){ref-type="table-fn"}                   Zip code               X                                                                                         X                                                        6

  Wang et al. ([@B114]), PBC (SEER)                         USA              1983--2012, FU: NA, 30--75+ yrs                                  293,471 NSCLC                                                                                                        3                                                                                                                    County                 X       1                                           X                                         X   X           X[^u^](#TN61){ref-type="table-fn"}   8

  Wang et al. ([@B115]), PBC (SEER)                         USA              1983--2012, FU: NA, all ages                                     56,220 SCLC                                                                                                          3                                                                                                                    County                 X       1,2,3,5                                     X                                         X   X           X[^u^](#TN61){ref-type="table-fn"}   8

  **AUSTRALIA/NEW ZEALAND**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Bonett et al. ([@B65]), PBC (REG)                         Australia        1977--1982, FU: 1983, all ages                                   2,934                                                                                                                X                                                                                                                    CD                     X                                                                                         X                                                        8

  Hall et al. ([@B81]), PBC                                 Australia        1982--1996, FU: ≥ 5 yrs, all ages                                9,080                                                                                                                                                                               5                                                     CD                     X       5                                       X                                             X   X           X[^A^](#TN67){ref-type="table-fn"}   8

  Tervonen et al. ([@B22]), PBC (REG)                       Australia        2000--2008, FU: 2008, all ages                                   26,415                                                                                                                                                                              5                                                     CD/SLA                 X                                                                                             X   X   X       X[^B^](#TN68){ref-type="table-fn"}   8

  Currow et al. ([@B72]), PBC (REG)                         Australia        2003--2007, FU: 2008, all ages                                   3,040 NSCLC                                                                                                                                                                         5                                                     POA                    X                                                                                             X   X           X[^D^](#TN69){ref-type="table-fn"}   8

  Denton et al. ([@B74]), PCo                               Australia        2001--2014 (case discussion),FU: NA, Mean age 68 ± 11 (SD) yrs   2,369                                                                                                                                                                               5                                                     POA                    X       5                                       X                                             X   X   X       X[^E^](#TN70){ref-type="table-fn"}   7

  Hui et al. ([@B84]), PBC (REG)                            Australia        1996, FU: ≥ 4 yrs, 32--91 yrs                                    526                                                                                                                                                                                 5                                                     POA                        X   KM                                      X   X                                                                                              6

  Stanbury et al. ([@B110]), PBC (REG)                      Australia        1991--2008, FU: 2008, 15--89 yrs                                 33,942                                                                                                                                                                              5                                                     LGA                            5                                           X[^6^](#TN32){ref-type="table-fn"}        X   X   X       X[^F^](#TN71){ref-type="table-fn"}   8

  Yu et al. ([@B119]), PBC (REG)                            Australia        1992--2000, FU: 2001, 15--89 yrs                                 15,251                                                                                                                                                                              5                                                     LGA                            5                                           X[^6^](#TN32){ref-type="table-fn"}        X   X   X       X[^F^](#TN71){ref-type="table-fn"}   8

  Jeffreys et al. ([@B36]), PBC (REG)                       NZ               1994--2003, FU: 2004, 15--99 yrs                                 13,643                                                                                                                                                                              4                                                     MB                                                                         X[^7^](#TN33){ref-type="table-fn"}        X                                                    7

  Sutherland and Aitken ([@B111]), RCo                      NZ               1997--1999, FU: ≥ 5 yrs,27--92yrs                                102                                                                                                                                                                                 10                                                    MB                             X[^12^](#TN38){ref-type="table-fn"}     X                                                                                                  4

  Haynes et al. ([@B83]), PBC                               NZ               1994--2001, FU: 2004, Mean age 69 yrs                            12,420                                                                                                                                                                              4                                                     CAU                    X                                                                                             X   X   X       X[^G^](#TN72){ref-type="table-fn"}   8

  **ASIA**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Ito et al. ([@B85]), PBC (REG)                            Japan            1993--2004, FU: ≥ 5 yrs,Age:NA                                   39,621                                                                                                                                                                              5                                                     Cho-Aza                        1,5                                         X[^13^](#TN39){ref-type="table-fn"}           X           X[^H^](#TN73){ref-type="table-fn"}   7

  Kwak and Kim ([@B91]), PBC (REG)                          Korea            2010--2011, FU: 2014, all ages                                   1,426                                                                                                                                                                               4                                                     Dong                   X       1,3,5                                   X                                             X   X   X   X   X[^L^](#TN74){ref-type="table-fn"}   8

  Kwak ([@B37]), PBC (REG)                                  Korea            2000--2011, FU: 2013, all ages                                   13,801                                                                                                                                                                              4                                                     Dong                   X   X   1,2,3, KM                               X                                             X   X                                                8
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*BMI, Body mass index; CAU, Census Area Unit; CBG, Census block group; CD, Census Collection District; CeT, Census tract; CSS, Cause-specific survival; DA, Dissemination area; EA, Enumeration area; ED, Enumeration district; ED-SCLC, Extensive disease small-cell lung cancer; FU, Follow-up length; HR, Hazard ratio; IND, Individual; IQR, Inter quartile range; KM, Study provided Kaplan-Meier-Curve(s) or other survival curves stratified by SES; LGA, Local Government Area; LSOA, Lower Super Output Area; MB, Meshblock; mth(s), month(s); NA, Not available; NCDB, National Cancer Data Base (American Cancer Society); NL, The Netherlands; NSCLC, Non-small cell lung cancer; NZ, New Zealand; OA, Output area; OS, Overall survival; PBC, Population-based cohort; PC, Postal code; PCo, Prospective cohort; POA, Postal code area; QS, Quality score; RCo, Retrospective cohort; REG, Registry; RS, Relative survival; SCLC, Small-cell lung cancer; SEER, Surveillance, Epidemiology, and End Results Program; SES, Socioeconomic status; SLA, Statistical Local Area; UK, United Kingdom; wks, Weeks; yrs, Years of age*;

*Data sources for survival data*;

*Only lung cancer patients*;

*Numbers indicate number of groups, excluding unknown/missing*;

*More details about SES levels in Table [S2](#SM2){ref-type="supplementary-material"}*;

*Adjustment by stratification and standardization was also considered; if both model and survival rates were calculated, only model adjustments are reported*;

*Study reported relative excess risk*;

*Study reported deprivation gap*;

*Rank order of % Gross domestic product expenditure on health*;

*Sample size for all cancers: USA n = 486,327, Canada n = 187,650*;

*Study reported survival rate ratios*;

*SES index has been measured on a continuous scale*;

*Survival rate: 6 weeks, 3 and 6 months, 1, 2, and 5 years, according to correspondence with author*;

*Study reported net survival*;

*Studies included same patient population*;

*Comorbidities, population density*;

*Chemotherapy, comorbidity, grade, histology, location of metastasis, period*;

*Presence of concomitant diseases*;

*Follow-up period, histology, treatment*;

*Follow-up period, period of diagnosis*;

*Comorbidity, resection, radiotherapy, chemotherapy*;

*Year of diagnosis*;

*Urban/rural*;

*Histology, performance status*;

*Marital status, north/south geographic zone, period of diagnosis, year of follow-up*;

*Cancer center catchment area, year of diagnosis*;

*Cancer center, chemotherapy, health insurance, histologic subtype, marital status, nativity, neighborhood ethnic enclave, radiation, surgery type, urban/rural, year of diagnosis*;

*Race/ethnicity, marital status*;

*Race, treatment, urban/rural, year of diagnosis*;

*Chemotherapy, ethnic origin, histologic grade, histology, marital status, radiation, surgery, tumor lobar location*;

*Chemotherapy, ethnicity, marital status, radiation, surgery*;

*Race, surgery*;

*Race, treatment, tumor grade*;

*Elderly concentration, place of residence, race, racial segregation, random census tract effect, surgery, tumor grade*;

*Histology, race, treatment, urban/rural, year of diagnosis*;

*Race*;

*Urban/rural, race, marital status, Medicaid, comorbidity, year of diagnosis, treatment, English speaking, health professional shortage area, health care provider supply characteristics*;

*Comorbidities, geographic location, grade, histological type, hospital volume, insurance status, lymph node status, marital status, race/ethnicity, teaching hospital, treatment*;

*Comorbidities, grade, insurance, lymph node status, race/ethnicity, tumor size, histology, surgery, radiation, chemotherapy*;

*Comorbidity, facility type, grade, histology, insurance, lymph nodes, primary tumor site, race, radiation before surgery, surgery, urban/rural, year of diagnosis*;

*Comorbidity, distance between residence and hospital, facility type, grade, histology, insurance, race, TN classification, tumor location, tumor size, chemotherapy, radiation fractions, radiation treatment time*;

*Calendar period, comorbidity, histology, indigenous status, insurance status, location/status of hospital, marital status, remoteness, surgical status*;

*Country of birth, remoteness, year of diagnosis*;

*Comorbidity, country of birth, histology, insurance status, local health districts, lung location, remoteness, resection*;

*Place of residence*;

*Follow-up year*;

*Ethnic group, travel to primary care, travel to cancer center*;

*Period of diagnosis*;

*BMI, diagnosis path (by regular checkup, by chance, by symptom), drinking*;

*Chemotherapy, ethnic origin, histologic grade, histology, radiation, surgery, tumor lobar location, tumor size, period of diagnosis*.

Regarding individual socioeconomic status, 16 studies measured educational attainment, eight studies measured income and eight studies assessed the occupation of the patients. Studies investigating area-based SES most often used an index (42 studies) or income measures (30 studies) with diverse levels of aggregation from postal codes in The Netherlands (\~8--17 households) ([@B63], [@B94], [@B106]) to comparisons of whole countries ([@B77], [@B113]). More details and definitions of socioeconomic measures and aggregated levels are provided in Table [S2](#SM2){ref-type="supplementary-material"}.

Association of individual SES and survival---modeling results
-------------------------------------------------------------

Detailed modeling results for all studies with individual measures are displayed in Table [S3](#SM3){ref-type="supplementary-material"}. The majority of studies adjusted for age, gender, stage, and treatment. Three studies adjusted for smoking ([@B44], [@B45], [@B47]) (Table [1](#T1){ref-type="table"}). Overall, there was no consistent difference in survival between studies with different levels of adjustment for prognostic factors (Figure [2](#F2){ref-type="fig"}).

![Meta-analyses of studies on the association of individual education / income (reference: high income/education) and survival after lung cancer. NSCLC, non-small cell lung cancer. Kravdal ([@B55]): highest educational group, men = 17+ years, women = 13--17+ years. Chang et al. ([@B46]): high income category = high individual AND high neighborhood income (reference), low income category = low individual AND low neighborhood income.](fonc-08-00536-g0002){#F2}

For individual education (Figure [2](#F2){ref-type="fig"}), nine studies ([@B44], [@B45], [@B47], [@B48], [@B54]--[@B56], [@B60], [@B61]) were included in the meta-analysis. The summary estimate from the random effects model revealed no association between education and lung cancer survival (hazard ratio (HR) 1.03, 95 % confidence interval (CI): 0.96--1.10). The results of these studies were rather heterogeneous (*I*^2^ = 54.76 %, *p* = 0.02). A stratified meta-analysis by stage at diagnosis was possible with three studies ([@B45], [@B48], [@B56]), but no significant associations were observed (early stage: HR 1.03, 95 % CI 0.92--1.15; late stage: HR 0.94, 95 % CI 0.81--1.08; Figure [S9](#SM1){ref-type="supplementary-material"}). We conducted stratified meta-analyses for studies that included stage, smoking or treatment in Cox models (Figures [S2](#SM10){ref-type="supplementary-material"}--[S4](#SM12){ref-type="supplementary-material"}). These analyses showed smaller effect estimates in studies that adjusted for stage (stage adjustment: HR 1.00, 95 % CI 0.92--1.08; no stage adjustment: HR 1.14, 95 % CI 1.05--1.23, Figure [S2](#SM10){ref-type="supplementary-material"}) or smoking status (smoking adjustment: HR 0.91, 95 % CI 0.72--1.14; no smoking adjustment: HR 1.04, 95 % CI 0.97--1.12, Figure [S3](#SM11){ref-type="supplementary-material"}), but confidence intervals were wide and overlapping. Stratified meta-analyses by studies that included treatment in Cox models did not suggest a difference in effect estimates (Figure [S4](#SM12){ref-type="supplementary-material"}). Three studies ([@B50], [@B51], [@B53]) were not included in the meta-analysis because of low scores for quality assessment. We conducted a sensitivity analysis by including these three studies into the meta-analysis. Results were similar to the main analysis (HR 1.05, 95 % CI 0.99--1.12, Figure [S5](#SM13){ref-type="supplementary-material"}).

For individual income (Figure [2](#F2){ref-type="fig"}), five studies ([@B45]--[@B48], [@B62]) were included in the meta-analysis showing a lower survival after lung cancer diagnosis for patients in the lowest income group compared to patients in the highest income group (HR 1.13, 95 % CI: 1.08--1.19). The studies were homogeneous (*I*^2^ = 0.00 %, *p* = 0.81). All studies included in the meta-analysis of individual income adjusted for stage (Table [1](#T1){ref-type="table"}). A stratified meta-analysis by smoking adjustment gave similar estimates as for the main analysis (smoking adjustment: HR 1.12, 95 % CI 1.03--1.22; no smoking adjustment: HR 1.14, 95 % CI 1.07--1.20, Figure [S6](#SM14){ref-type="supplementary-material"}). Exclusion of one study not adjusting for treatment ([@B62]) resulted in a marginal change of estimate (HR 1.13, 95 % CI 1.08--1.18, Figure [S7](#SM15){ref-type="supplementary-material"}). One study was not included in the meta-analysis because of reporting on a continuous scale ([@B34]) and indicated an association between higher income and lower risk of death after lung cancer diagnosis (Table [S3](#SM3){ref-type="supplementary-material"}).

Individual occupation was investigated in three studies ([@B32], [@B45], [@B55]) (Table [S3](#SM3){ref-type="supplementary-material"}). As the measures were very heterogeneous, a meta-analysis was not possible. In summary, no lower survival with decreasing SES was reported for occupational groups. Fujino ([@B32]) conducted analyses stratified by gender and reported a higher risk of dying after lung cancer diagnosis for housewives (women) and unemployed women compared to employed women but he did not consider other confounding factors besides gender. Kravdal ([@B55]) stratified occupational groups by education and reported for the low educational group a lower risk of death in non-manual occupations and a lower survival in farmers compared to manual occupations within the same educational group (Table [S3](#SM3){ref-type="supplementary-material"}). High-level non-manual occupations with medium education had a lower risk compared to low educated manual occupations ([@B55]).

No study reported hazard ratios for the association between an individually measured SES index and lung cancer survival (Table [1](#T1){ref-type="table"}).

Association of area-based SES and survival---modeling results
-------------------------------------------------------------

Characteristics of SES exposure of most studies on area-based SES measurements were too heterogeneous to conduct meta-analyses. However, for studies reporting hazard ratios for SES group comparisons, the hazard ratios for low SES vs. high SES (reference) are shown in Figure [3](#F3){ref-type="fig"} (education), Figure [4](#F4){ref-type="fig"} (income) and Figure [5](#F5){ref-type="fig"} (index), sorted by region and area-level (small to large). Figure [6](#F6){ref-type="fig"} additionally displays a meta-analysis for studies on area-based income from the US. Ten studies were not displayed in figures because they did not report confidence intervals ([@B43], [@B73], [@B83], [@B109]), did not show results ([@B65]), assessed SES on a continuous scale ([@B6], [@B34], [@B80], [@B116]) or did not use low or high SES as reference category ([@B67]). Results of all studies are reported in detail in Table [S4](#SM4){ref-type="supplementary-material"}.

![Association of area-based education (reference: high education) and survival after lung cancer. Order: small to large area level. NSCLC, non-small cell lung cancer.](fonc-08-00536-g0003){#F3}

![Association of area-based income (reference: high income) and survival after lung cancer. Order: small to large area level. NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.](fonc-08-00536-g0004){#F4}

![Association of area-based index measures (reference: high socioeconomic group) and survival after lung cancer. Order: region and small to large area level. NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; UK, United Kingdom.](fonc-08-00536-g0005){#F5}

![Meta-analysis of studies from the United States on the association of area-based income (reference: high income) and survival after lung cancer. Order: small to large area level. NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.](fonc-08-00536-g0006){#F6}

Three studies ([@B88]--[@B90]) investigated area-based measurements of education and all reported a lower survival after lung cancer diagnosis in areas with the lowest education levels (Figure [3](#F3){ref-type="fig"}, Table [S4](#SM4){ref-type="supplementary-material"}). All studies adjusted for age, sex, and stage at diagnosis and included patients diagnosed with NSCLC residing in the US. The extent of the association did not depend on the size of area-level (Figure [3](#F3){ref-type="fig"}). Results of area-based studies were more homogeneous and reported stronger associations compared to studies investigating individual education.

The association between area-based income and lung cancer survival was investigated in 19 studies ([@B34], [@B43], [@B64]--[@B67], [@B73], [@B80], [@B88]--[@B90], [@B95], [@B96], [@B98], [@B109], [@B112], [@B114], [@B115], [@B117]). Twelve studies ([@B64], [@B66], [@B88]--[@B90], [@B95], [@B96], [@B98], [@B112], [@B114], [@B115], [@B117]) displayed in Figure [4](#F4){ref-type="fig"} in general show a lower survival for the lowest income group compared to the highest group (range: HR 1.03--1.24, Figure [4](#F4){ref-type="fig"}). Estimates of seven studies ([@B64], [@B88]--[@B90], [@B98], [@B112], [@B117]) adjusting for stage at diagnosis were similar to estimates of studies not adjusting for stage (Table [2](#T2){ref-type="table"}, Figure [4](#F4){ref-type="fig"}). The meta-analyses of six US studies ([@B88], [@B90], [@B98], [@B112], [@B114], [@B115]) revealed a slightly larger summary estimate for the smaller area-level of census tracts (HR 1.15, 95 % CI 1.09--1.21, Figure [6](#F6){ref-type="fig"}) than for the two larger area-levels zip code and county (zip code: HR 1.08, 95 % CI 1.03--1.13; county: HR 1.06, 95 % CI 1.06--1.07, Figure [6](#F6){ref-type="fig"}). However, not all of these studies adjusted for stage, which hampers their comparability. Two studies had been excluded from this meta-analysis due to overlapping study populations. The study by McMillan et al. ([@B96]) has overlapping population with the study by Khullar et al. ([@B90]). We decided to include Khullar et al. ([@B90]) in our meta-analysis as all stages were analyzed compared to McMillan et al. ([@B96]) which included solely patients diagnosed with stage III. We excluded the study by Yang et al. ([@B117]) because there is overlapping population with the study by Tannenbaum et al. ([@B112]). Although Tannenbaum et al. ([@B112]) included solely patients diagnosed with non-small cell lung cancer, they included a longer period of diagnosis compared to Yang et al. ([@B117]).

The majority of studies reported lower survival in lower income areas (Table [S4](#SM4){ref-type="supplementary-material"}).

Twenty-two studies reported hazard ratios on the association between an area-based SES index measure and lung cancer survival ([@B5], [@B6], [@B22], [@B37], [@B63], [@B70], [@B72]--[@B74], [@B79], [@B81]--[@B83], [@B86], [@B91]--[@B94], [@B101], [@B105]--[@B107], [@B116]) (Table [S4](#SM4){ref-type="supplementary-material"}). Group comparisons of 18 studies ([@B5], [@B22], [@B37], [@B63], [@B70], [@B72], [@B74], [@B79], [@B81], [@B82], [@B86], [@B91]--[@B94], [@B101], [@B105]--[@B107]) showed significant associations between lower income areas and a lower survival after lung cancer diagnosis in 10 studies ([@B5], [@B22], [@B37], [@B70], [@B79], [@B82], [@B92], [@B93], [@B101], [@B106]), with a range of HR 1.05--2.21 (Figure [5](#F5){ref-type="fig"}). Nine studies ([@B5], [@B22], [@B74], [@B79], [@B91]--[@B93], [@B105], [@B107]) adjusted for stage at diagnosis (Table [2](#T2){ref-type="table"}). Notably, no study reported a hazard ratio below 1.00. Within-country comparisons did not reveal a tendency for larger or smaller estimates depending on the size of the area-level (Figure [5](#F5){ref-type="fig"}).

The majority of studies adjusted for age, gender and stage. Two income studies ([@B112], [@B117]) and two SES index studies ([@B6], [@B91]) included smoking status in their models (Table [2](#T2){ref-type="table"}). The latter two studies reported slightly lower estimates than studies without adjustment for smoking (Table [S4](#SM4){ref-type="supplementary-material"}).

Combined effects of individual and area-based SES---modeling results
--------------------------------------------------------------------

Two studies investigated both individual and area-based SES ([@B34], [@B82]). However, only one study investigated directly combined effects of individual and area-based income ([@B34]). These analyses are based on a population size of *N* = 78 patients with stage II NSCLC and showed a significantly lower survival only for higher individual income. In the combined model, the area-level variable did not add any explanatory power to the model including individual income ([@B34]) (Table [S4](#SM4){ref-type="supplementary-material"}). The other study analyzed area-based SES with adjustment for individual SES in the Cox model ([@B82]). The study reported a significant association between lower area-level SES and lung cancer survival in both models with and without adjustment for individual SES ([@B82]). The estimate of the model including individual SES adjustment was considerably smaller (including individual SES: HR 1.43, 95 % CI 1.07--1.91; without individual SES: HR 2.21, 95 % CI 1.69--2.90).

SES and survival time, survival rate, and other survival measures
-----------------------------------------------------------------

Overall, 67 studies ([@B6], [@B30], [@B33], [@B35], [@B37]--[@B39], [@B42]--[@B46], [@B49], [@B50], [@B52], [@B53], [@B57], [@B59]--[@B64], [@B66]--[@B71], [@B73]--[@B81], [@B84]--[@B87], [@B90], [@B91], [@B93]--[@B95], [@B97]--[@B104], [@B106]--[@B108], [@B110]--[@B115], [@B117]--[@B119]) reported median survival time or survival rates after lung cancer stratified by SES (Tables [S5](#SM5){ref-type="supplementary-material"}, [S6](#SM6){ref-type="supplementary-material"}). Fifteen ([@B30], [@B39], [@B42], [@B44]--[@B46], [@B49], [@B50], [@B52], [@B53], [@B57], [@B59]--[@B62]) and 52 studies ([@B6], [@B29], [@B33], [@B35], [@B37], [@B38], [@B43], [@B63], [@B64], [@B66]--[@B71], [@B73]--[@B81], [@B84]--[@B87], [@B90], [@B91], [@B93]--[@B95], [@B97]--[@B104], [@B106]--[@B108], [@B110]--[@B115], [@B117]--[@B119]) used an individual or area-based SES measure, respectively. Nine individual ([@B30], [@B39], [@B42], [@B45], [@B46], [@B49], [@B50], [@B59], [@B62]) and 45 area-based ([@B6], [@B29], [@B33], [@B35]--[@B38], [@B43], [@B63], [@B64], [@B66]--[@B69], [@B73]--[@B76], [@B78]--[@B81], [@B84]--[@B87], [@B90], [@B93]--[@B95], [@B97]--[@B101], [@B104], [@B106], [@B107], [@B110]--[@B112], [@B114], [@B115], [@B117], [@B118]) SES studies reported lower lung cancer survival in lower SES groups (Tables [S5](#SM5){ref-type="supplementary-material"}, [S6](#SM6){ref-type="supplementary-material"}). The remaining 6 individual ([@B44], [@B52], [@B53], [@B57], [@B60], [@B61]) and 9 area-based ([@B36], [@B70], [@B71], [@B77], [@B91], [@B103], [@B108], [@B113], [@B119]) studies reported no difference or no gradient across socioeconomic categories in survival time or survival rates.

Forty-one studies ([@B33], [@B35], [@B36], [@B39], [@B42], [@B43], [@B46], [@B49], [@B52], [@B57], [@B59]--[@B61], [@B66], [@B67], [@B71], [@B73]-- [@B77], [@B80], [@B81], [@B85], [@B86], [@B90], [@B91], [@B95], [@B98], [@B101]--[@B103], [@B106], [@B107], [@B110]--[@B114], [@B118], [@B119]) reported 5-year survival after lung cancer diagnosis and 30 ([@B33], [@B35], [@B36], [@B39], [@B42], [@B43], [@B46], [@B49], [@B59], [@B66], [@B67], [@B71], [@B73]--[@B76], [@B80], [@B81], [@B85], [@B90], [@B95], [@B98], [@B101], [@B106], [@B107], [@B110]--[@B112], [@B114], [@B119]) of these showed lower survival rates in lower SES groups (Tables [S5](#SM5){ref-type="supplementary-material"}, [S6](#SM6){ref-type="supplementary-material"}). The range of differences between survival rates for lowest and highest SES groups was larger in studies considering area-based SES than in studies assessing individual SES (Individual SES: range 1.0--12.8 % units; area-based SES: range 0.9--22.9 % units, Tables [S5](#SM5){ref-type="supplementary-material"}, [S6](#SM6){ref-type="supplementary-material"}) but did not depend on the SES measure or the population size of the area. When we compared area-based US studies, studies using the smaller census tract level ([@B33], [@B43], [@B67], [@B76], [@B80], [@B98], [@B112]) reported larger differences in 5-year survival between high and low income areas. But those studies also observed a larger range of differences in survival rates (1.0--22.9 %) than studies assessing SES by zip codes ([@B90]) and counties ([@B114]) (range 1.2--7.7 %, Table [S6](#SM6){ref-type="supplementary-material"}).

Differences in survival between highest and lowest SES groups were similar when comparing studies reporting 1 or 3-year survival rates (1-year survival: range 1.4--11 %; 3-year survival: range 0.4--11 %, Tables [S5](#SM5){ref-type="supplementary-material"}, [S6](#SM6){ref-type="supplementary-material"}). In general, there was no distinct pattern regarding higher effect sizes in studies showing shorter survival rates.

One individual study ([@B58]) and four area-based studies ([@B35], [@B41], [@B110], [@B119]) calculated the relative excess risk (RER) and indicated a lower risk for higher SES groups (Tables [S5](#SM5){ref-type="supplementary-material"}, [S6](#SM6){ref-type="supplementary-material"}). Eight area-based studies ([@B31], [@B36], [@B40], [@B71], [@B75], [@B85], [@B103], [@B108]) used the deprivation gap which indicates the survival difference between the highest and lowest SES group and is mostly used in the UK. All of these studies reported a negative deprivation gap, meaning that the highest SES group has a higher survival rate than the lowest SES group (Table [S6](#SM6){ref-type="supplementary-material"}).

Risk of bias
------------

Table [S7](#SM7){ref-type="supplementary-material"} displays the risk of bias assessment for included studies according to a modified Newcastle-Ottawa-Scale. Overall, the mean quality scores of individual and area-based studies were rather in line, both ranging from 7 to 8 out of 8 points. As the majority used data of national or regional cancer registries, many studies scored high within the categories selection and outcome, representing for example adequacy of follow-up or representativeness of study population.

Both funnel plots for the meta-analyses of individual education and income studies did not reveal any asymmetry (Education: Begg\'s test *p* = 0.13, Egger\'s test *p* = 0.07, Figure [S8](#SM16){ref-type="supplementary-material"}; income: Begg\'s test *p* = 0.38, Egger\'s test *p* = 0.34, Figure [S9](#SM17){ref-type="supplementary-material"}). The funnel plot of individual education analysis appeared to be cylindrical which might be due to the larger heterogeneity between these studies (Figure [2](#F2){ref-type="fig"} and Figure [S8](#SM16){ref-type="supplementary-material"}).

Discussion {#s4}
==========

This systematic review provides a comprehensive overview of the current literature on socioeconomic differences in lung cancer survival by including both individual and area-based measurements of socioeconomic status. Meta-analyses for individual SES and lung cancer survival revealed a weak association for studies using income measures but no consistent association for education measures. For studies using individual income measures, no consistent difference across level of adjustment for smoking status was observed and stratified meta-analyses by stage and treatment were not possible. For individual education, results indicated that adjusting for stage and smoking status might result in smaller effect estimates. Studies using occupational measures did not report lower lung cancer survival with decreasing SES. Group comparisons for hazard ratios of area-based studies indicated lower survival for lower SES irrespective of the socioeconomic measure. Meta-analyses for US studies reporting on area-based income showed a slightly larger estimate for the smaller geographical unit census tract compared to zip code and county level. However, comprehensiveness of adjustment was different across these studies. For the remaining area-based studies, the extent of association did not depend on the size of area-level but most studies reported a hazard ratio above 1.00. Compared to model results of individual SES studies, area-based studies in general reported stronger associations between SES and survival. Most studies reporting on survival time and survival rates revealed lower lung cancer survival in lower socioeconomic groups, not depending on individual or different area levels.

Compared to results for other cancer types, the association between individual income and survival after lung cancer diagnosis was weak. Cancers occurring in lung tissue are mostly detected in later stages ([@B120]) which limits opportunities for cancer therapy ([@B121]). Nevertheless, despite good treatment options for some patients, survival is still rather low ([@B121]). Given these circumstances, the effect of SES on differences in lung cancer survival might be not as relevant as for other cancer types. The smaller effect estimates for individual education studies adjusting for stage at diagnosis supports this assumption, as this cancer type is mainly diagnosed at later stages ([@B120]). For cancers of intermediate or good prognosis, such as colorectal or breast, higher relative risks were observed ([@B10], [@B122]).

Results of meta-analyses including individual education compared to income were rather different. This was an unexpected finding as other systematic reviews reported lower survival in low educational groups for several cancer types ([@B20]), such as breast ([@B10]) and prostate cancer ([@B12]). Furthermore, educational attainment influences occupational status which as well determines income ([@B20]). One explanation might be that many income studies were conducted in countries where income has a higher impact on access to and quality of health care; however, significant associations were as well reported in Scandinavian countries with universal health care systems.

Summary estimates of meta-analyses for individual and area-based income were similar, especially in studies using the smaller geographical unit US census tract. This was an unexpected finding as all area-based studies included in the meta-analyses were conducted in the US, a country with a non-universal health care system, and individual income studies included both types of health care systems. Therefore, we would have expected larger effect sizes for studies conducted in the United States but due to area-based measurements of income, effects might have been diluted. The comparisons of different area-level income studies revealed a slightly higher summary estimate for the smaller US census tract unit. However, not all of these studies adjusted for stage at diagnosis. Our results partly confirm results of a study comparing SES measures for different geographical units in two US states in which census tract SES measures detected gradients in all-cause mortality more consistently compared to zip code level SES measures ([@B123]). In contrast, another study examining area-based SES variables at census tract and zip code level reported small differences in effect estimates of self-rated health ([@B124]). In other countries, we could not observe larger effect sizes for studies using smaller areas consistently, but studies reported rather heterogeneously. Group comparisons of area-based studies using composite measures of SES did not reveal stronger or more consistent associations depending on the size of the geographical unit, although no study reported a HR below 1.00. This result does not confirm the discussion about the importance of the use of smaller area-levels to minimize or avoid ecological fallacy ([@B20], [@B125]). Due to the lack of individual index studies, it was not possible to compare area-based index studies with individual studies, thus we cannot exclude ecological bias.

One study ([@B34]) included in our systematic review investigated directly combined effects of individual and area-based income and reported the aggregated median income on US census tract level to not add any explanatory power to the model including individual income. In this study, area-based income was not valuable as proxy measure for individual income, however, it might be reasonable to interpret area-based income as its own concept, for example regarding access to health care. The study by Greenwald and colleagues ([@B34]) included only a small number (*N* = 78) of patients diagnosed with stage II lung cancer resident in the US. To further explore differences and relationships between individual and aggregated SES measures in the context of lung cancer survival, larger studies conducted in different countries are required.

The level of adjustment for prognostic factors was very heterogeneous across studies. Most studies adjusted for age, gender, and stage and many studies additionally included variables for treatment and comorbidity. Although strongly associated with lung cancer incidence, mortality, and survival ([@B126]), smoking was only considered by three individual ([@B44], [@B45], [@B47]) and five area-based studies ([@B6], [@B75], [@B91], [@B112], [@B117]). Our meta-analyses stratified by adjustment for smoking suggested lower effect estimates for individual education studies adjusting for smoking status which indicates the importance of controlling for this prognostic factor. A recent analysis confirmed the contribution of smoking to socioeconomic inequalities in mortality among 14 European countries ([@B127]). Since many individual studies, especially in Scandinavia, used cancer registry data and linked these data to other registries for the socioeconomic status, there might be no information on individual smoking status. Area-based studies using census data could have linked their data to area-based information on smoking status by other censuses or administrative sources. Such an approach should be considered in future studies.

Mechanisms that might lead to socioeconomic differences in lung cancer survival can include factors related to diagnosis, treatment modalities, and patients themselves ([@B20]). Access to health care can be both influenced by the affluence of a country or a residential area and the individual. More deprived areas can have less health care resources which could result in a delay in diagnosis and delay in start of treatment ([@B20]). However, a meta-analysis on the effect of SES on stage at lung cancer diagnosis did not reveal an association ([@B18]). The stratified meta-analysis of individual education studies in the present review did as well not show any differences which confirm the results of Forrest and colleagues ([@B18]). For cancer therapy, socioeconomic differences have been reported regarding the administration of specific treatments as well as the referral to specialists or to oncology centers ([@B20]). For instance, lung and breast cancer patients belonging to deprived groups were less frequently treated by surgery in a study from England ([@B128]). Due to the lack of studies stratifying by treatment in the present review we could not investigate this issue.

Our study has important strengths and some limitations. The current literature search was conducted in four databases, which might have missed out relevant articles. We restricted our search terms to only "lung cancer" due to the large amount of search results when using the term "cancer." This might be the reason why the number of articles found through searching reference list of included papers was high. Nevertheless, the amount of detected literature through database search was still rather large and it was possible to include databases specialized to the social sciences to assure inclusion of articles not only indexed in biomedical science focused databases. In addition, we enhanced the quality of extracted data by contacting authors if results were not reported clearly or incompletely to give a comprehensive view of all included studies. While we cannot completely rule out the presence of a publication bias, which would lead to an overestimation of socioeconomic differences in cancer survival, our funnel plots for the meta-analyses did not reveal asymmetries suggesting that the probability of publication bias is rather low.

In general, studies were very heterogeneous, not only in the use of socioeconomic measures and aggregated levels but also in reporting of survival measures and in the level of adjustment. The studies have been conducted in several countries around the world including very different settings. The adjustment for key prognostic factors such as stage was often not possible. Thus, like in most epidemiologic studies, we cannot rule out that findings might be influenced by confounding. Furthermore, our comparisons of summary estimates across subgroups (e.g., by adjustment and aggregation level) were not based on statistical tests and observed trends might be chance findings. Thus, comparison of results across studies and the conclusions derived from this review must be interpreted with caution.

The generalizability of our results to low-income countries is limited, as they were highly underrepresented and no study from Africa or South America was found. One reason for this might be the restriction to publications in English or German language in our literature search. In our study, most individual studies were conducted in Scandinavian countries and most area-based studies were conducted in the US or United Kingdom. For other European countries as well as Asian countries, further studies are needed.

We did not carry out meta-analyses stratified by gender. Considering papers with the largest study populations included in our review, studies reported in general a higher survival in women compared to men. However, the majority of these studies also reported similar results for women and men regarding a potential gradient according to SES. This was true for both individual and aggregated SES measurements.

Although the Newcastle-Ottawa-Scale (NOS) is a tool for quality assessment of studies which is widely used, there is some critique about its validity ([@B129]). However, the NOS gives an overview of the quality of included articles and helps to exclude studies that are not suitable to be included in a meta-analysis. We excluded three studies from our meta-analyses because of a low quality score. These studies were also less comparable to the other studies due to other reasons: The first study used data from clinical trials ([@B50]) and was therefore not representative of the underlying population, the second study only reported univariate hazard ratios without adjustment ([@B53]) and the third study used data of 24 institutions which could voluntarily participate in the study ([@B51]). As the cut-off quality score was not set a priori, a sensitivity analysis including these three studies was conducted and revealed similar estimates. Another limitation was that there is no specific NOS coding manual for studies relying on registry data. We used the manual for cohort studies, therefore many registry studies were rated too low in the outcome section because they did not describe how mortality data were collected although it could be assumed that these data were retrieved by administrative sources with good quality ([@B130]). On the other hand, studies using registry data might be awarded too many points (stars) in the comparability section as their quality of measurement of potential confounders might not be as high as in usual cohort studies.

The interpretation and summary of both model and survival rate results among studies remained difficult due to diversity in SES measurements used, in particular across different countries or continents. In their review on socioeconomic differences and the risk of lung or colorectal cancer, Kuznetsov and Mielck ([@B17]) already found very heterogeneously reported SES measurements and therefore could not conduct a meta-analysis. However, we were still able to perform meta-analyses by using hazard ratios of the lowest and highest socioeconomic group which was reported by most studies. Furthermore, we focused on model results of the studies, as most studies that reported survival rates showed age-standardized rates without any further adjustment for other prognostic factors. Our restriction of using the highest and lowest SES categories for comparing the model results enabled us to conduct meta-analyses with studies assessing the SES on different categories like tertiles or quintiles. The downside of this approach is that we compared different levels of SES (e.g., the lower quintile might correspond to a lower SES as compared to the lower tertile). However, as studies reported SES measures heterogeneously, this was the only way to show summarized measures for the effect of SES on lung cancer survival.

Another limitation was that it was not possible to perform stratified meta-analyses by subtypes of lung cancer because no individual study reported on SCLC patients only. Nevertheless, meta-analyses of other important prognostic factors (stage, treatment, and smoking) were conducted and revealed no major differences compared to the main analyses.

In conclusion, the body of evidence in this review provides some support for the hypothesis that lower individual income is associated with a lower survival after lung cancer diagnosis. There was no evidence for an association between individual education or occupation and lung cancer survival. Group comparisons for hazard ratios of area-based studies indicated lower survival for lower SES groups, irrespective of the socioeconomic measure. However, effect sizes are generally smaller than and not as consistent as found for other cancer types. Future research should focus on a combined analysis of individual and aggregated SES measures, for example by constructing aggregated measures from individual data. This approach would allow to investigate associations between survival and both individual and aggregated measures, whilst also taking prognostic factors such as stage and smoking into account. Furthermore, a standardized socioeconomic measure would be desirable to enhance comparability across nations and across different levels of aggregation.
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